Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Gilead Sciences |
---|---|
Information provided by: | Gilead Sciences |
ClinicalTrials.gov Identifier: | NCT00036634 |
This study will look at two doses of GS-7340-02 versus tenofovir DF.
Condition | Intervention | Phase |
---|---|---|
HIV Infections |
Drug: GS-7340-02 |
Phase I Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Phase 1/2, Randomized, Double-Blind, Active Controlled, Dose Escalation Study of the Safety, Tolerance, Pharmacokinetic,, and Antiviral Activity of GS-7340-02 in Antiretroviral-Naive Patients Who Are Chronically Infected With HIV-1 |
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria
Exclusion Criteria
United States, California | |
Stanford Positive Care Program | |
Palo Alto, California, United States, 94304 | |
United States, Illinois | |
Protocare Trials Chicago Center for Clinical Trials | |
Chicago, Illinois, United States, 60610 | |
United States, New York | |
Rockefeller University Hospital | |
New York, New York, United States, 10021 |
Study ID Numbers: | GS-120-1101 |
Study First Received: | May 13, 2002 |
Last Updated: | June 23, 2005 |
ClinicalTrials.gov Identifier: | NCT00036634 |
Health Authority: | United States: Food and Drug Administration |
treatment naive |
Virus Diseases Sexually Transmitted Diseases, Viral HIV Infections Sexually Transmitted Diseases Acquired Immunodeficiency Syndrome |
Tenofovir Retroviridae Infections Immunologic Deficiency Syndromes Tenofovir disoproxil |
RNA Virus Infections Slow Virus Diseases Immune System Diseases Lentivirus Infections Infection |